Chan, Emily

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 1,764

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine

Drug-Induced Adverse ReactionsMonoclonal and Polyclonal Antibodies Research

Cited by 1,521

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer

Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 697

Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation

Raisner, R., Kharbanda, S., Jin, L., Jeng, E., Chan, E., Merchant, M., Haverty, P. M., Bainer, R., Cheung, T., Arnott, D., et al. (2018) · Cell Reports

Genomics and Chromatin DynamicsChromatin Remodeling and Cancer

Cited by 375

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer

Hippo pathway signaling and YAP/TAZMicrotubule and mitosis dynamics

Cited by 215

Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer

Jin, L., Garcia, J., Chan, E., de la Cruz, C., Segal, E., Merchant, M., Kharbanda, S., Raisner, R., Haverty, P. M., Modrusan, Z., et al. (2017) · Cancer Research

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 153

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Tolcher, A. W., Berlin, J. D., Cosaert, J., Kauh, J., Chan, E., Piha-Paul, S. A., Amaya, A., Tang, S., Driscoll, K., Kimbung, R., et al. (2017) · Cancer Chemotherapy and Pharmacology

TGF-β signaling in diseasesCancer Immunotherapy and Biomarkers

Cited by 105

Abstract 3327: Discovery and characterization of the potent, allosteric SHP2 inhibitor GDC-1971 for the treatment of RTK/RAS driven tumors

Williams, B., Taylor, A., Orozco, O., Owen, C., Kelley, E., Lescarbeau, A., Shortsleeves, K., Kipp, R., Nguyen, V., Brophy, E., et al. (2022) · Cancer Research

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 7